Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 Biomarker disease BEFREE Tamoxifen, raloxifene, and aromatase inhibitors were associated with lower risk of primary invasive breast cancer in women but also were associated with adverse effects that differed between medications. 31479143 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 Biomarker disease BEFREE Tamoxifen, raloxifene, and the aromatase inhibitors exemestane and anastrozole reduce invasive breast cancer in women without preexisting breast cancer, but also cause adverse effects that vary by medication. 31509915 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 GeneticVariation disease BEFREE In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; 2 trials), and aromatase inhibitors (RR, 0.45 [95% CI, 0.26-0.70]; 2 trials) were associated with lower risks of invasive breast cancer compared with placebo; results were not specific to mutation carriers. 31429902 2019
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 Biomarker disease BEFREE Our preliminary immunohistochemical analysis of 221 invasive breast cancer cases indicated that 87.3% (193/221) had at least 5% aromatase positive cells. 28489882 2017
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 AlteredExpression disease BEFREE In breast cancer, LRH-1 expression is associated with invasive breast cancer; positively correlates with ERα status and aromatase activity; and promotes oestrogen-dependent cell proliferation. 20817789 2010
Entrez Id: 1588
Gene Symbol: CYP19A1
CYP19A1
0.060 Biomarker disease BEFREE Prognostic significance of the intratumoral mRNA expression of three enzymes related to in situ estrogen biosynthesis, i.e., aromatase, sulfatase, and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), was evaluated in patients with invasive breast cancer. 12796397 2003